1-20 of 89 Search Results for

*

Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis

Torben Ek, Raghda R Ibrahim, Hartmut Vogt, Kleopatra Georgantzi, Catarina Träger, Jennie Gaarder, Anna Djos, Ida Rahmqvist, Elisabeth Mellström, Fani Pujol-Calderón, Christoffer Vannas, Lina Hansson, Henrik Fagman, Diana Treis, Susanne Fransson, Tobias Österlund, Tzu-Po Chuang, Bronte Manouk Verhoeven, Anders Ståhlberg, Ruth H Palmer, Bengt Hallberg, Tommy Martinsson, Per Kogner, Martin Dalin
Journal: Cancer Research Communications
Cancer Research Communications (2024)
https://doi.org/10.1158/2767-9764.CRC-24-0338
Published: 23 August 2024
View article titled, Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis
Open the PDF for Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis in another window
Includes: Supplementary data
Journal Articles

First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Duncan A. Wheatley, Rossana Berardi, Miguel A. Climent Duran, Anna Tomiak, Alastair P. Greystoke, Anthony M. Joshua, Hendrik-Tobias Arkenau, Lajos Géczi, Javier Garciá Corbacho, Luis G. Paz-Ares, Syed A. Hussain, Lubos Petruželka, Angelo Delmonte, Colombe Chappey, Joanna C. Masters, Elisabete Michelon, Danielle A. Murphy, Sandrine Mwewa, Rossano Cesari, Bernard Doger de Spéville
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (6): 1609–1619.
https://doi.org/10.1158/2767-9764.CRC-23-0459
Published: 28 June 2024
View article titled, First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Open the PDF for First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study in another window
Includes: Supplementary data
Journal Articles

Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of Rac-1

Ling He, Angeliki Ioannidis, Carter J. Hoffman, Evelyn Arambula, Purva Joshi, Julian Whitelegge, Linda M. Liau, Harley I. Kornblum, Frank Pajonk
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (6): 1566–1580.
https://doi.org/10.1158/2767-9764.CRC-24-0049
Published: 25 June 2024
View article titled, Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of <em>Rac-1</em>
Open the PDF for Activation of the Mevalonate Pathway in Response to Anti-cancer Treatments Drives Glioblastoma Recurrences Through Activation of <em>Rac-1</em> in another window
Includes: Supplementary data
Journal Articles

Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis

Armin Rashidi, Maryam Ebadi, Tauseef U. Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Mohammad H. Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda J. Kabage, Sharon Lopez, Sivapriya Ramamoorthy, Shernan G. Holtan, Daniel J. Weisdorf, Alexander Khoruts, Christopher Staley
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (6): 1454–1466.
https://doi.org/10.1158/2767-9764.CRC-24-0138
Published: 10 June 2024
View article titled, Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis
Open the PDF for Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Nicholas J. Hornstein, Mohammad A. Zeineddine, Betul B. Gunes, Andrew J. Pellatt, Mark Knafl, Haifeng Zhu, Anneleis F. Willett, Abdelrahman Yousef, Suyu Liu, Ryan Sun, Andrew Futreal, Scott E. Woodman, Melissa W. Taggart, Michael J. Overman, Daniel M. Halperin, Kanwal P. Raghav, John Paul Shen
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (5): 1363–1368.
https://doi.org/10.1158/2767-9764.CRC-24-0019
Published: 29 May 2024
View article titled, Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma
Open the PDF for Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma

Elizabeth I. Buchbinder, Justine V. Cohen, Giuseppe Tarantino, Christine G. Lian, David Liu, Rizwan Haq, F. Stephen Hodi, Donald P. Lawrence, Anita Giobbie-Hurder, Deborah Knoerzer, Ryan J. Sullivan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (5): 1321–1327.
https://doi.org/10.1158/2767-9764.CRC-24-0036
Published: 21 May 2024
View article titled, A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Open the PDF for A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy

Gopika SenthilKumar, Aronne M. Schottstaedt, Lindsay L. Peterson, Lauren N. Pedersen, Christopher R. Chitambar, Alexis Vistocky, Anjishnu Banerjee, John M. Longo, Tracy Kelly, Adam Currey, Melinda R. Stolley, Carmen Bergom
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (5): 1211–1226.
https://doi.org/10.1158/2767-9764.CRC-23-0148
Published: 07 May 2024
View article titled, Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Open the PDF for Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy, Mitesh J. Borad, Rastilav Bahleda, Cesar A. Perez, Li-Tzong Chen, Shumei Kato, Do-Youn Oh, Paul Severson, Betty Y. Tam, Cheng S. Quah, James J. Harding
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1165–1173.
https://doi.org/10.1158/2767-9764.CRC-24-0137
Published: 30 April 2024
View article titled, A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Open the PDF for A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Impact of Surgery-Induced Myeloid-derived Suppressor Cells and the NOX2/ROS Axis on Postoperative Survival in Human Pancreatic Cancer

Hanna Grauers Wiktorin, Ebru Aydin, Roberta Kiffin, Caroline Vilhav, Johan Bourghardt Fagman, Mustafa Kaya, Sanchari Paul, Beatrice Westman, Svein Olav Bratlie, Peter Naredi, Kristoffer Hellstrand, Anna Martner
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1135–1149.
https://doi.org/10.1158/2767-9764.CRC-23-0447
Published: 25 April 2024
View article titled, Impact of Surgery-Induced Myeloid-derived Suppressor Cells and the NOX2/ROS Axis on Postoperative Survival in Human Pancreatic Cancer
Open the PDF for Impact of Surgery-Induced Myeloid-derived Suppressor Cells and the NOX2/ROS Axis on Postoperative Survival in Human Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Disparities in Access to Liver Transplant Referral and Evaluation among Patients with Hepatocellular Carcinoma in Georgia

Katherine Ross-Driscoll, Arrey-Takor Ayuk-Arrey, Raymond Lynch, Lauren E. McCullough, Giorgio Roccaro, Lauren Nephew, Jonathan Hundley, Raymond A. Rubin, Rachel Patzer
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1111–1119.
https://doi.org/10.1158/2767-9764.CRC-23-0541
Published: 22 April 2024
View article titled, Disparities in Access to Liver Transplant Referral and Evaluation among Patients with Hepatocellular Carcinoma in Georgia
Open the PDF for Disparities in Access to Liver Transplant Referral and Evaluation among Patients with Hepatocellular Carcinoma in Georgia in another window
Includes: Supplementary data
Journal Articles

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1100–1110.
https://doi.org/10.1158/2767-9764.CRC-24-0082
Published: 18 April 2024
View article titled, First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance

Rola Saouaf, Yibin Xie, Sungjin Kim, Yaniv Raphael, Christopher Nguyen, Daniel Luthringer, Timothy J. Daskivich, Eric Lo, Mourad Tighiouart, Debiao Li, Hyung L. Kim
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (3): 938–945.
https://doi.org/10.1158/2767-9764.CRC-24-0009
Published: 27 March 2024
View article titled, High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance
Open the PDF for High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance in another window
Includes: Supplementary data
Journal Articles

Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models

Axel Sahovaler, Michael S. Valic, Jason L. Townson, Harley H.L. Chan, Mark Zheng, Sharon Tzelnick, Tiziana Mondello, Alon Pener-Tessler, Donovan Eu, Abdullah El-Sayes, Lili Ding, Juan Chen, Catriona M. Douglas, Robert Weersink, Nidal Muhanna, Gang Zheng, Jonathan C. Irish
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (3): 796–810.
https://doi.org/10.1158/2767-9764.CRC-23-0269
Published: 15 March 2024
View article titled, Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models
Open the PDF for Nanoparticle-mediated Photodynamic Therapy as a Method to Ablate Oral Cavity Squamous Cell Carcinoma in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Priya Kumthekar, Sawyer Jacobson, Imane El Dika, Amin Yaqubie, Juan Lopez, Binhui Huang, Yi-Wei Tang, Yujia Wen, Lawrence H. Schwartz, Anthony B. El-Khoueiry, Jennifer J. Knox, Lakshmi Rajdev, Monica M. Bertagnolli, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Alan P. Venook
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (3): 682–690.
https://doi.org/10.1158/2767-9764.CRC-22-0516
Published: 07 March 2024
View article titled, CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Laura F. Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M. Soyfer, Jiarui Liu, Jane H. Chen, Nitya Mehrotra, Xin Huang, Heidi E. Kosiorek, Amylou Dueck, Alexander Himstead, Elena Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M. Scherber, Ruben A. Mesa, Katrine L. Whiteson, Andrew Odegaard, Angela G. Fleischman
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (3): 660–670.
https://doi.org/10.1158/2767-9764.CRC-23-0380
Published: 05 March 2024
View article titled, The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Open the PDF for The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence in another window
Includes: Supplementary data
Journal Articles

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Rhonda L. Bitting, Janet A. Tooze, Michael Goodman, Donald C. Vile, Jessica M. Brown, Christopher Y. Thomas, Morgan Neve, Mitra Kooshki, Safoa Addo, Pierre L. Triozzi, Purnima Dubey
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (2): 530–539.
https://doi.org/10.1158/2767-9764.CRC-23-0436
Published: 26 February 2024
View article titled, Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
Open the PDF for Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Enrique Sanz-Garcia, Samantha Brown, Jessica A. Lavery, Jessica Weiss, Hannah E. Fuchs, Ashley Newcomb, Asha Postle, Jeremy L. Warner, Michele L. LeNoue-Newton, Shawn M. Sweeney, Shirin Pillai, Celeste Yu, Chelsea Nichols, Brooke Mastrogiacomo, Ritika Kundra, Nikolaus Schultz, Kenneth L. Kehl, Gregory J. Riely, Deborah Schrag, Anand Govindarajan, Katherine S. Panageas, Philippe L. Bedard
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (2): 475–486.
https://doi.org/10.1158/2767-9764.CRC-23-0409
Published: 20 February 2024
View article titled, Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Open the PDF for Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry in another window
Includes: Supplementary data
Journal Articles

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Vivek Subbiah, Niamh Coleman, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Jordi Rodon, Shubham Pant, Ecaterina E. Ileana Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (2): 378–387.
https://doi.org/10.1158/2767-9764.CRC-22-0260
Published: 12 February 2024
View article titled, Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <em>mTOR/AKT/PI3K</em> Pathway Alterations and Advanced Solid Malignancies
Open the PDF for Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <em>mTOR/AKT/PI3K</em> Pathway Alterations and Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (1): 226–235.
https://doi.org/10.1158/2767-9764.CRC-23-0313
Published: 29 January 2024
View article titled, Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
Open the PDF for Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer

Maira Soto, Erin L. Filbert, Hai Yang, Stephanie Starzinski, Alec Starzinski, Marissa Gin, Brandon Chen, Phi Le, Tony Li, Brandon Bol, Alexander Cheung, Li Zhang, Frank J. Hsu, Andrew Ko, Lawrence Fong, Bridget P. Keenan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (1): 200–212.
https://doi.org/10.1158/2767-9764.CRC-23-0550
Published: 25 January 2024
View article titled, Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer
Open the PDF for Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer in another window
Includes: Supplementary data